8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Range of invasive meningococcal disease sequelae and health economic application – a systematic and clinical review

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Invasive meningococcal disease (IMD) is uncommon, life-threatening, with many diverse sequelae. The aims were to: 1) comprehensively characterise the sequelae; 2) have a systematic application for sequelae impact in economic evaluation (EE).

          Methods

          Sequelae categorised as physical/neurological or psychological/behavioural were identified from a systematic review of IMD observational studies (OS) and EEs in high-income countries (published 2001–2020). A comprehensive map and EE-relevant list, respectively, included physical/neurological sequelae reported in ≥2OS and ≥ 2OS + 2EE (≥1OS and ≥ 1OS + 1EE for psychological/behavioural). Sequelae proportions were selected from the highest quality studies reporting most sequelae. Three medical experts independently evaluated the clinical impact of findings.

          Results

          Sixty-Six OS and 34 EE reported IMD sequelae. The comprehensive map included 44 sequelae (30 physical/neurological, 14 psychological/behavioural), of which 18 (14 physical/neurological and 4 psychological/behavioural) were EE-relevant. Experts validated the study and identified gaps due to limited evidence, underreporting of psychological/behavioural sequelae in survivors/their families, and occurrence of multiple sequelae in the acute phase and long-term.

          Conclusions

          The considerable burden of IMD sequelae on survivors and their families is potentially underestimated in EE, due to underreporting and poorly-defined subtle sequelae. When assessing IMD burden and potential interventions e.g., vaccination, sequelae range and duration, underreporting, and indirect burden on dependents should be considered.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12889-022-13342-2.

          Highlights

          Invasive meningococcal disease survivors frequently suffer from variable sequelae.

          A broad sequelae map plus those relevant to economic evaluation (EE) were defined.

          Forty-four sequelae were selected: 30 physical/neurological and 14 psychological/behavioural.

          Eighteen EE-relevant sequelae included 14 physical/neurological and 4 psychological/behavioural

          Underreporting, family impact and multiple sequelae cases were critical gaps.

          A video summary linked to this article can be found on Figshare: 10.6084/m9.figshare.19753840.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12889-022-13342-2.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data

          Background Streptococcus pneumoniae, Haemophilus influenzae , and Neisseria meningitidis , which are typically transmitted via respiratory droplets, are leading causes of invasive diseases, including bacteraemic pneumonia and meningitis, and of secondary infections subsequent to post-viral respiratory disease. The aim of this study was to investigate the incidence of invasive disease due to these pathogens during the early months of the COVID-19 pandemic. Methods In this prospective analysis of surveillance data, laboratories in 26 countries and territories across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae , and N meningitidis from Jan 1, 2018, to May, 31, 2020, as part of the Invasive Respiratory Infection Surveillance (IRIS) Initiative. Numbers of weekly cases in 2020 were compared with corresponding data for 2018 and 2019. Data for invasive disease due to Streptococcus agalactiae , a non-respiratory pathogen, were collected from nine laboratories for comparison. The stringency of COVID-19 containment measures was quantified using the Oxford COVID-19 Government Response Tracker. Changes in population movements were assessed using Google COVID-19 Community Mobility Reports. Interrupted time-series modelling quantified changes in the incidence of invasive disease due to S pneumoniae, H influenzae , and N meningitidis in 2020 relative to when containment measures were imposed. Findings 27 laboratories from 26 countries and territories submitted data to the IRIS Initiative for S pneumoniae (62 837 total cases), 24 laboratories from 24 countries submitted data for H influenzae (7796 total cases), and 21 laboratories from 21 countries submitted data for N meningitidis (5877 total cases). All countries and territories had experienced a significant and sustained reduction in invasive diseases due to S pneumoniae, H influenzae , and N meningitidis in early 2020 (Jan 1 to May 31, 2020), coinciding with the introduction of COVID-19 containment measures in each country. By contrast, no significant changes in the incidence of invasive S agalactiae infections were observed. Similar trends were observed across most countries and territories despite differing stringency in COVID-19 control policies. The incidence of reported S pneumoniae infections decreased by 68% at 4 weeks (incidence rate ratio 0·32 [95% CI 0·27–0·37]) and 82% at 8 weeks (0·18 [0·14–0·23]) following the week in which significant changes in population movements were recorded. Interpretation The introduction of COVID-19 containment policies and public information campaigns likely reduced transmission of S pneumoniae, H influenzae , and N meningitidis , leading to a significant reduction in life-threatening invasive diseases in many countries worldwide. Funding Wellcome Trust (UK), Robert Koch Institute (Germany), Federal Ministry of Health (Germany), Pfizer, Merck, Health Protection Surveillance Centre (Ireland), SpID-Net project (Ireland), European Centre for Disease Prevention and Control (European Union), Horizon 2020 (European Commission), Ministry of Health (Poland), National Programme of Antibiotic Protection (Poland), Ministry of Science and Higher Education (Poland), Agencia de Salut Pública de Catalunya (Spain), Sant Joan de Deu Foundation (Spain), Knut and Alice Wallenberg Foundation (Sweden), Swedish Research Council (Sweden), Region Stockholm (Sweden), Federal Office of Public Health of Switzerland (Switzerland), and French Public Health Agency (France).
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Review of guidelines for good practice in decision-analytic modelling in health technology assessment

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England

                Bookmark

                Author and article information

                Contributors
                KINGA.H.MESZAROS@GSK.COM
                Journal
                BMC Public Health
                BMC Public Health
                BMC Public Health
                BioMed Central (London )
                1471-2458
                31 May 2022
                31 May 2022
                2022
                : 22
                : 1078
                Affiliations
                [1 ]GRID grid.425090.a, ISNI 0000 0004 0468 9597, GSK, ; Avenue Fleming, 20 1300 Wavre, Belgium
                [2 ]Present address: Takeda Pharmaceutical Company Limited, Zurich, Switzerland
                [3 ]GRID grid.425090.a, ISNI 0000 0004 0468 9597, GSK, , Freelance C/O GSK, ; Wavre, Belgium
                [4 ]GRID grid.418019.5, ISNI 0000 0004 0393 4335, GSK, ; Rockville, USA
                [5 ]GRID grid.11794.3a, ISNI 0000000109410645, Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, , University of Santiago, ; Santiago de Compostela, Spain
                [6 ]GRID grid.411048.8, ISNI 0000 0000 8816 6945, Department of Pediatrics, Translational Pediatrics and Infectious Diseases, , Hospital Clínico Universitario de Santiago de Compostela, ; Santiago de Compostela, Spain
                [7 ]GRID grid.512891.6, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), ; Madrid, Spain
                Article
                13342
                10.1186/s12889-022-13342-2
                9153861
                35641955
                626eb78b-40a7-4c5e-bdbc-467dbd06b550
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 11 January 2022
                : 18 April 2022
                Categories
                Research
                Custom metadata
                © The Author(s) 2022

                Public health
                meningococcal infection,sequelae,economic evaluation,systematic review
                Public health
                meningococcal infection, sequelae, economic evaluation, systematic review

                Comments

                Comment on this article